Author: qvanteq

Katharina Gegenschatz-Schmid, Stefano Buzzi, Jonas Grossmann, Bernd Roschitzki, Riccardo Urbanet, Roman Heuberger, Dorothea Glück, Arik Zucker, Martin Ehrbar Blood-contacting medical implants made of Nitinol and other titanium alloys, such as neurovascular flow diverters and peripheral stents, have the disadvantage of being highly thrombogenic. This makes the use of systemic (dual) anti-platelet / anticoagulant therapies inevitable […]

Qvanteq AG has developed a surface modification – not a coating – that renders titanium alloy-based implants antithrombogenic. Extensive studies have shown that the modified surface suppresses the activation of proteins of the blood coagulation cascade. The technology can be extended from titanium alloys to virtually any material used in medical devices and is therefore […]

Qvanteq, togehter with partners, has developed a process that can render any material, or medical devices made up from a combination of materials, antithrombotic. For inquiries please contact the company.  

Qvanteq AG is using MedtechVault for secure communication with its notified body, suppliers and customers. About MedtechVault: MedtechVault is the ideal solution for  efficient document and data exchange in the medical device and in-vitro diagnostics industry. MedtechVault enables secure communication between the economic operators like legal manufacturers, [critical] suppliers, authorized representatives, distributors, importers as well […]

Qvanteq AG has developed a fast and simple method to screen materials used for medical devices with respect to their thrombus formation capacity. Respective work is normally done using whole human blood. For inquiries please contact the company.

Qvanteq AG has moved into new offices at the Technopark in Zürich.

Differential protein adsorption of surface treated Nitinol alloys regulates blood activation K Gegenschatz-Schmid, S Buzzi, J Grossmann, B Roschitzki, D Glück, A Zucker, M Ehrbar Recent research results were presented at the 2019 Annual Meeting of the Swiss Society for Biomaterials + Regenerative Medicine. Abstract: Stents were developed for overcoming heart attacks and strokes caused […]

Qvanteq completed ISO13485:2016 re-certification under the guidance of the notified body DEKRA.

In collaboration with academic institutions, Qvanteq has developed the capability for dynamic testing of any type of cardiovascular device in a blood loop model (Chandler Loop) using fresh whole human blood. This capability is also available for collaborations.

Qvanteq completed ISO13485 re-certification under the guidance of the notified body DEKRA.

Qvanteq AG completed a financing round. It provides the company with sufficient cash to further develop its technology for vascular stents such as intracranial stents and flow diverters.

In vivo data involving Qvanteq’s surface technology was published in the April issue of the journal Eurointervention.

Qvanteq AG today announced that its QUEST I study was completed. The technology has shown safety in humans.

The topic of this 18 month program is the “Investigation of in vitro response of human blood to Qvanteq’s anti-thrombotic and pro-healing surface technology applied on vascular stents”.  

Qvanteq AG today announced that it completed enrollment of QUEST I study patients.